SAN MATEO, Calif., March 05, 2018 (GLOBE NEWSWIRE) — Adherium (ASX:ADR), announced the presentation of new study results utilizing the SmartinhalerTM technology at the Joint Congress of the American Academy of Allergy, Asthma and Immunology, and the World Allergy Organization, March 3rd in Orlando, Florida.
Dr. Andrew G. Weinstein of Asthma Management Systems, Rockland, Delaware presented Validation of The Asthma Adherence Management Model, finding that physicians implementing an Asthma Adherence Pathway were successful in promoting adherence to the recommended usage of a long-acting beta agonist and inhaled corticosteroid for a treatment group, at 81 percent, and improved the treatment group’s asthma control compared to patients in a control group.
Co-authors included Dr. Deborah A. Gentile and Erica Butler of Pediatric Alliance, Pittsburgh; Dr. Anil Singh, Dr. Rihab Sharara, Dr. Kiet Ma, Dr. Tariq Cheema, Jennifer Maiolo and Allison Kong of Allegheny Health Network, Pittsburgh; and Dr. David P. Skoner of the West Virginia University School of Medicine, Pittsburgh.
The study was designed to examine how objective monitoring, identification of barriers, delivery of barrier-specific adherence strategies and enhanced communication skills can promote adherence to asthma treatments. Forty patients with asthma were randomly assigned to a treatment group, or a control group, and completed a three month prospective nested study of the Asthma Adherence Pathway WebApp. Physicians utilized a common long-acting beta agonist and inhaled corticosteroid following standard guidelines. Patients admitted to the study had poor asthma control defined by an Asthma Control Questionnaire. Patients in the treatment group utilized the Asthma Adherence Pathway WebApp to identify adherence barriers, and then monitored monthly for adherence with an Adherium SmartinhalerTM sensor. Treatment subjects were given feedback regarding adherence findings. Treatment adherence was determined by the mean of four measures over three months. Physicians in the group utilizing the Asthma Adherence Pathway WebApp and SmartinhalerTM sensor were trained in motivational interviewing, using strategies from the WebApp to promote adherence. Patients in the control group were not monitored for adherence.
Mean treatment adherence in the treatment group was 81 percent. Results showed the treatment group experienced greater improvement (0.75 ACQ units) than the control group (0.19 ACQ units). The treatment group had 13 subjects achieve Minimal Important Difference (defined as an improvement of greater than or equal to 0.5 units on the ACQ), compared to six patients in the control group.
“Our clinical track record continues to expand,” said Arik Anderson, CEO of Adherium. “We have distributed more than 100,000 devices through commercial channels and clinical studies across more than 30 countries, including the US, UK, Singapore and Australia. In addition, our software and devices have been subject to studies and articles in more than 70 clinical publications. We believe the science is right, that technology – if correctly applied – can close the care gap in asthma and other chronic conditions.”
About Adherium
Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of connected medical devices for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in the USA, Europe and Australasia. Learn more at Adherium.com.
Inquiries
Vik Panda, Adherium
Email: vikp@adherium.com
Media
Chris Gale, Greentarget
Phone: 646.695.2883
Email: cgale@greentarget.com
Investors
Leigh Salvo, Gilmartin Group
Phone: 415.937.5404
Email: leigh@gilmartinir.com
